Imsidolimab

Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases[1][2].

Product Specifications

CAS Number

[2102543-86-0]

Product Name Alternative

ANB 019

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/imsidolimab.html

Purity

98.63

Solubility

10 mM in DMSO

Smiles

[Imsidolimab]

Molecular Weight

(146.6 kDa)

References & Citations

[1]Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87 (3) : AB70.|[2]Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22 (9) :4344.